Merrill Lynch Upgrades Pfizer (PFE) to Buy
More News related to PFE
- Pfizer's Novel HIV/AIDS Treatment SELZENTRY(TM) Becomes the Latest Fully Approved Antiretrovial for Treatment-Experienced HIV Patients
- Beacon Equity Issues Technical Trade Alerts on Drug Manufacturers: NVS, JNJ, PFE, GSK, ABT, AZN
- Pfizer Withdraws Application to Switch Viagra to Non-Prescription Status in Europe
- Quarterly Data Confirms Hedge Funds Exited Stocks In A Big Way
- Pacific Energy Resources Ltd. Announces Third Quarter 2008 Operating and Financial Results
More News related to Upgrades
- BMO Upgrades Spectrum Brands (SPC) to Market Perform
- Maxim Upgrades Palomar Medical (PMTI) to Buy
- RBC Capital Upgrades DSP Group (DSPG) to Sector Perform
- UBS Upgrades Morgans Hotel Group (MHGC) to Buy
- Janney Montgomery Scott Upgrades Wright Express Corp (WXS) to Buy.
Merrill Lynch upgrades Pfizer (NYSE: PFE) from Underperform to Buy, citing the company's dividend yield and business.
Pfizer's dividend yield is currently 6.8%.
Pfizer, Inc. engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.
Related Categories
UpgradesStocks Mentioned
+0.74Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
